Version 1
: Received: 12 April 2024 / Approved: 15 April 2024 / Online: 15 April 2024 (10:45:33 CEST)
How to cite:
Masucci, M.; Ernberg, I.; Karlsson, C.; Blomqvist, L.B. Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine. Preprints2024, 2024040950. https://doi.org/10.20944/preprints202404.0950.v1
Masucci, M.; Ernberg, I.; Karlsson, C.; Blomqvist, L.B. Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine. Preprints 2024, 2024040950. https://doi.org/10.20944/preprints202404.0950.v1
Masucci, M.; Ernberg, I.; Karlsson, C.; Blomqvist, L.B. Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine. Preprints2024, 2024040950. https://doi.org/10.20944/preprints202404.0950.v1
APA Style
Masucci, M., Ernberg, I., Karlsson, C., & Blomqvist, L.B. (2024). Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine. Preprints. https://doi.org/10.20944/preprints202404.0950.v1
Chicago/Turabian Style
Masucci, M., Claes Karlsson and Lennart Blomqvist Blomqvist. 2024 "Bridging the Divide – a Review on the Implementation of Personalized Cancer Medicine" Preprints. https://doi.org/10.20944/preprints202404.0950.v1
Abstract
The shift towards Personalized Cancer Medicine (PCM) represents a significant transformation in cancer care, emphasizing tailored treatments based on genetic understanding of cancer at the cellular level. This review draws on recent literature to explore key factors influencing PCM implementation, highlighting the role of innovative leadership, interdisciplinary collaboration, and coordinated funding and regulatory strategies. Success in PCM relies on overcoming challenges such as integrating diverse medical disciplines, securing sustainable investment for shared infrastructures, and navigating complex regulatory landscapes. Effective leadership is crucial for fostering a culture of innovation and teamwork, essential for translating complex biological insights into personalized treatment strategies. The transition to PCM necessitates not only organizational adaptation but also the development of new professional roles and training programs, underscoring the need for a multidisciplinary approach and the importance of team science in overcoming the limitations of traditional medical paradigms. The conclusion underscores that PCM's success hinges on creating collaborative environments that support innovation, adaptability, and shared vision among all stakeholders involved in cancer care.
Keywords
individualised medicine; precision medicine; personalized medicine; stratified medicine; translational cancer research; cancer care; oncology; evidence based medicine; team science; management; scientific leadership; organization
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
